Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Gilead Sciences has sold Amygdala Neurosciences the rights to GS-6637, a small-molecule ALDH2 inhibitor with the potential to treat behavior and substance addictions by preventing dopamine surges. Former executives of CV Therapeutics, which Gilead bought in 2009, formed Amygdala to acquire GS-6637. According to Amygdala, Gilead invented GS-6637 based on an initial series of inhibitors synthesized by CV. Amygdala says it plans to start Phase II clinical trials this year.
This article has been sent to the following recipient: